Dong Sung Bio Pharm.Co.,Ltd. (002210.KS)
KRW 4345.0
(9.72%)
KRW 4345.0
(9.72%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -2.07 Billion KRW | 2.25% |
| 2022 | -2.12 Billion KRW | 50.81% |
| 2021 | -4.31 Billion KRW | 69.37% |
| 2020 | -14.07 Billion KRW | -67.9% |
| 2019 | -8.38 Billion KRW | -45.97% |
| 2018 | -5.74 Billion KRW | -2797.43% |
| 2017 | -198.26 Million KRW | 88.06% |
| 2016 | -1.66 Billion KRW | -465.06% |
| 2015 | 454.83 Million KRW | 104.15% |
| 2014 | -10.94 Billion KRW | -450.59% |
| 2013 | -1.98 Billion KRW | -162.29% |
| 2012 | 3.19 Billion KRW | 87.65% |
| 2011 | 1.7 Billion KRW | 121.43% |
| 2010 | -7.93 Billion KRW | -1496.36% |
| 2009 | 568.43 Million KRW | -84.45% |
| 2008 | 3.65 Billion KRW | 37.68% |
| 2007 | 2.65 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -163.39 Million KRW | 91.78% |
| 2024 Q2 | -1.05 Billion KRW | -548.72% |
| 2023 Q2 | -812.87 Million KRW | -205.35% |
| 2023 Q1 | 771.58 Million KRW | 222.02% |
| 2023 Q4 | -1.98 Billion KRW | -4352.05% |
| 2023 FY | -2.07 Billion KRW | 2.25% |
| 2023 Q3 | -44.65 Million KRW | 94.51% |
| 2022 Q3 | 1.4 Billion KRW | 196.31% |
| 2022 Q4 | -632.35 Million KRW | -145.04% |
| 2022 FY | -2.12 Billion KRW | 50.81% |
| 2022 Q1 | -1.43 Billion KRW | 51.66% |
| 2022 Q2 | -1.45 Billion KRW | -1.55% |
| 2021 Q3 | -518.66 Million KRW | -364.63% |
| 2021 Q4 | -2.96 Billion KRW | -472.57% |
| 2021 Q1 | -712.85 Million KRW | 89.05% |
| 2021 Q2 | -111.62 Million KRW | 84.34% |
| 2021 FY | -4.31 Billion KRW | 69.37% |
| 2020 Q1 | -5.08 Billion KRW | -6.83% |
| 2020 FY | -14.07 Billion KRW | -67.9% |
| 2020 Q2 | 44.6 Million KRW | 100.88% |
| 2020 Q3 | -2.52 Billion KRW | -5759.42% |
| 2020 Q4 | -6.51 Billion KRW | -157.91% |
| 2019 Q3 | 226.29 Million KRW | 109.87% |
| 2019 Q2 | -2.29 Billion KRW | -47.33% |
| 2019 Q1 | -1.55 Billion KRW | -124.9% |
| 2019 FY | -8.38 Billion KRW | -45.97% |
| 2019 Q4 | -4.76 Billion KRW | -2205.18% |
| 2018 FY | -5.74 Billion KRW | -2797.43% |
| 2018 Q2 | 1.23 Billion KRW | 305.27% |
| 2018 Q4 | 6.24 Billion KRW | 149.48% |
| 2018 Q1 | -602.26 Million KRW | 42.77% |
| 2018 Q3 | -12.62 Billion KRW | -1121.27% |
| 2017 FY | -198.26 Million KRW | 88.06% |
| 2017 Q2 | 216.78 Million KRW | -17.84% |
| 2017 Q1 | 263.84 Million KRW | 90.15% |
| 2017 Q4 | -1.05 Billion KRW | -381.76% |
| 2017 Q3 | 373.49 Million KRW | 72.29% |
| 2016 Q3 | -677.71 Million KRW | 47.2% |
| 2016 FY | -1.66 Billion KRW | -465.06% |
| 2016 Q4 | 138.75 Million KRW | 120.47% |
| 2016 Q1 | 162.02 Million KRW | 177.6% |
| 2016 Q2 | -1.28 Billion KRW | -892.16% |
| 2015 FY | 454.83 Million KRW | 104.15% |
| 2015 Q4 | -208.8 Million KRW | 63.74% |
| 2015 Q3 | -575.79 Million KRW | -312.04% |
| 2015 Q2 | 271.55 Million KRW | -71.94% |
| 2015 Q1 | 967.88 Million KRW | 108.45% |
| 2014 FY | -10.94 Billion KRW | -450.59% |
| 2014 Q2 | 141.37 Million KRW | -37.98% |
| 2014 Q4 | -11.45 Billion KRW | -8538.94% |
| 2014 Q3 | 135.7 Million KRW | -4.01% |
| 2014 Q1 | 227.95 Million KRW | 110.25% |
| 2013 Q1 | 717.66 Million KRW | 425.07% |
| 2013 Q2 | -89.43 Million KRW | -112.46% |
| 2013 Q3 | -391.57 Million KRW | -337.84% |
| 2013 FY | -1.98 Billion KRW | -162.29% |
| 2013 Q4 | -2.22 Billion KRW | -468.18% |
| 2012 Q4 | -220.77 Million KRW | -222.41% |
| 2012 Q3 | 180.35 Million KRW | -88.11% |
| 2012 Q2 | 1.51 Billion KRW | -0.7% |
| 2012 Q1 | 1.52 Billion KRW | 0.0% |
| 2012 FY | 3.19 Billion KRW | 87.65% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 FY | 1.7 Billion KRW | 121.43% |
| 2011 Q3 | 391.88 Million KRW | -58.71% |
| 2011 Q2 | 949.05 Million KRW | 42.38% |
| 2011 Q1 | 666.55 Million KRW | 108.75% |
| 2010 Q3 | 45.39 Million KRW | 119.64% |
| 2010 FY | -7.93 Billion KRW | -1496.36% |
| 2010 Q4 | -7.61 Billion KRW | -16884.21% |
| 2010 Q1 | -132.43 Million KRW | 67.19% |
| 2010 Q2 | -231.11 Million KRW | -74.51% |
| 2009 Q3 | 187.86 Million KRW | -3.91% |
| 2009 Q1 | 588.69 Million KRW | 135.48% |
| 2009 FY | 568.43 Million KRW | -84.45% |
| 2009 Q2 | 195.51 Million KRW | -66.79% |
| 2009 Q4 | -403.64 Million KRW | -314.86% |
| 2008 Q2 | 1.48 Billion KRW | -65.93% |
| 2008 Q1 | 4.34 Billion KRW | 400.63% |
| 2008 FY | 3.65 Billion KRW | 37.68% |
| 2008 Q4 | -1.65 Billion KRW | -225.51% |
| 2008 Q3 | -509.77 Million KRW | -134.43% |
| 2007 Q1 | 741.73 Million KRW | 0.0% |
| 2007 Q4 | -1.44 Billion KRW | -908.79% |
| 2007 FY | 2.65 Billion KRW | 0.0% |
| 2007 Q2 | 3.18 Billion KRW | 328.85% |
| 2007 Q3 | 178.71 Million KRW | -94.38% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Dongwha Pharm.Co.,Ltd | 27.43 Billion KRW | 107.558% |
| Yuhan Corporation | 93.5 Billion KRW | 102.218% |
| Yuhan Corporation | 93.5 Billion KRW | 102.218% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 71.119% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 71.119% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 71.119% |
| Ildong Holdings Co., Ltd. | -59.58 Billion KRW | 96.52% |
| Samil Pharmaceutical Co.,Ltd | 1.66 Billion KRW | 224.668% |
| Dong-A Socio Holdings Co., Ltd. | 57.98 Billion KRW | 103.576% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 105.604% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 105.604% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 105.604% |
| SAMSUNG PHARM. Co., LTD. | -24.81 Billion KRW | 91.642% |
| Chong Kun Dang Holdings Corp. | 47 Billion KRW | 104.412% |
| HANDOK Inc. | -28.79 Billion KRW | 92.798% |
| Jeil Pharma Holdings Inc | -16.24 Billion KRW | 87.237% |
| Kukje Pharma Co., Ltd. | -8.41 Billion KRW | 75.355% |
| Bukwang Pharmaceutical Co., Ltd. | -31.32 Billion KRW | 93.38% |
| Aprogen pharmaceuticals,Inc. | -118.26 Billion KRW | 98.246% |
| Ilsung Pharmaceuticals Co., Ltd. | -20.94 Billion KRW | 90.096% |
| Daewon Pharmaceutical Co., Ltd. | 23.91 Billion KRW | 108.671% |
| Yungjin Pharm. Co., Ltd. | -3.87 Billion KRW | 46.487% |
| Boryung Corporation | 40.2 Billion KRW | 105.159% |
| Hyundai Pharmaceutical Co., Ltd. | 6.12 Billion KRW | 133.878% |
| Samjin Pharmaceuticals Co., Ltd. | 18.9 Billion KRW | 110.97% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 17.256% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 17.256% |
| Suheung Co., Ltd. | 6.11 Billion KRW | 133.892% |
| Kwang Dong Pharmaceutical Co., Ltd. | 36.96 Billion KRW | 105.61% |
| Hanall Biopharma Co.,Ltd | 3.5 Billion KRW | 159.109% |
| Whan In Pharm Co.,Ltd. | 29.77 Billion KRW | 106.965% |
| MYUNGMOON Pharm co.,Ltd | -4.52 Billion KRW | 54.166% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 96.382% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 96.382% |
| Korea United Pharm Inc. | 48.26 Billion KRW | 104.297% |
| CKD Bio Corp. | -24.19 Billion KRW | 91.427% |
| Daewoong pharmaceutical Co.,Ltd | 111.5 Billion KRW | 101.86% |
| JW Holdings Corporation | 19.02 Billion KRW | 110.9% |
| REYON Pharmaceutical Co., Ltd. | 3.58 Billion KRW | 157.876% |
| Hanmi Pharm. Co., Ltd. | 146.23 Billion KRW | 101.418% |
| Dong-A ST Co., Ltd. | 11.12 Billion KRW | 118.646% |
| Chong Kun Dang Pharmaceutical Corp. | 212.52 Billion KRW | 100.976% |
| JW Lifescience Corporation | 28.14 Billion KRW | 107.369% |
| Ildong Pharmaceutical Co., Ltd. | -78.92 Billion KRW | 97.372% |
| Jeil Pharmaceutical Co.,Ltd | 5 Billion KRW | 141.439% |
| Hana Pharm Co., Ltd. | 22.33 Billion KRW | 109.286% |